{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:40Z","timestamp":1786120360609,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/inf.0b013e31823e1e34","type":"journal-article","created":{"date-parts":[[2011,11,18]],"date-time":"2011-11-18T06:19:56Z","timestamp":1321597196000},"page":"e15-e23","source":"Crossref","is-referenced-by-count":12,"title":["A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers"],"prefix":"10.1097","volume":"31","author":[{"given":"Jodie","family":"McVernon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20210202","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"R2-17-20210202","first-page":"1","article-title":"Annual report of the Australian meningococcal surveillance programme, 2007amended.","volume":"33","author":"Tapsall","year":"2009","journal-title":"Commun Dis Intell"},{"key":"R3-17-20210202","first-page":"R49","article-title":". Changing patterns of case ascertainment and trends in meningococcal disease in England and Wales.","volume":"7","author":"Ramsay","year":"1997","journal-title":"Commun Dis Rep CDR Rev"},{"key":"R4-17-20210202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5694\/j.1326-5377.2007.tb00828.x","article-title":". Impact of meningococcal C conjugate vaccine use in Australia.","volume":"186","author":"Booy","year":"2007","journal-title":"Med J Aust"},{"key":"R5-17-20210202","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/INF.0b013e3181accde8","article-title":". Modern trends in mortality from meningococcal disease in Australia.","volume":"28","author":"Simpkins","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R6-17-20210202","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":". Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R7-17-20210202","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(02)08679-8","article-title":"Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination.","volume":"359","author":"Maiden","year":"2002","journal-title":"Lancet"},{"key":"R8-17-20210202","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/erv.09.48","article-title":"Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.","volume":"8","author":"Trotter","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R10-17-20210202","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(02)07716-4","article-title":". W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001.","volume":"359","author":"Hahne","year":"2002","journal-title":"Lancet"},{"key":"R11-17-20210202","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.tmaid.2009.12.001","article-title":"Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine.","volume":"8","author":"Broker","year":"2010","journal-title":"Travel Med Infect Dis"},{"key":"R12-17-20210202","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2147\/TCRM.S962","article-title":"Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.","volume":"4","author":"Kimmel","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"R14-17-20210202","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies.","volume":"127","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"R15-17-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"R16-17-20210202","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":". Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"R17-17-20210202","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1128\/CVI.00207-09","article-title":". Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.","volume":"16","author":"Reisinger","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"R18-17-20210202","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/INF.0b013e31818a0237","article-title":". A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.","volume":"28","author":"Jackson","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R19-17-20210202","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.vaccine.2009.10.104","article-title":". Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age.","volume":"28","author":"Black","year":"2010","journal-title":"Vaccine"},{"key":"R21-17-20210202","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":". Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine.","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R22-17-20210202","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/INF.0b013e31820e8638","article-title":". Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada.","volume":"30","author":"De Wals","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R23-17-20210202","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10096-009-0848-8","article-title":". Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.","volume":"29","author":"Halperin","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R24-17-20210202","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0b013e31818e037d","article-title":". Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.","volume":"28","author":"Perrett","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R25-17-20210202","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":". A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"R26-17-20210202","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":". Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial.","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"R27-17-20210202","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":". An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"R28-17-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1086\/317646","article-title":". Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.","volume":"183","author":"Richmond","year":"2001","journal-title":"J Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0b013e31823e1e34","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:26:20Z","timestamp":1786047980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006454-201201000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0b013e31823e1e34","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}